Lipoprotein disorders and dyslipidaemia
Primary and secondary dyslipidaemias, familial hypercholesterolaemia, Lp(a), LDL targets by risk, and the order of statin, ezetimibe, PCSK9 and other therapies.
Tier 1Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- LDL causes atherosclerosis. Lower is better, and the absolute benefit depends on baseline risk and how far LDL falls (about 22% fewer events per 1 mmol/L).
- Decide intensity from absolute CVD risk (Australian CVD risk calculator) or established ASCVD, not from the cholesterol alone.
- Established ASCVD: LDL under 1.4 mmol/L and a 50% cut. Statin, then ezetimibe, then a PCSK9 inhibitor.
Loading the rest of the note…
Finished reading?
Sources
- Australian guideline for assessing and managing cardiovascular disease riskAU/NZCommonwealth of Australia (Australian Chronic Disease Prevention Alliance), 2023
- Brieger D, Cullen L, Briffa T et al. Comprehensive Australian clinical guideline for diagnosing and managing acute coronary syndromes 2025. Heart Lung Circ 2025;34(4):309-397. doi:10.1016/j.hlc.2025.02.102. Erratum: Heart Lung Circ 2026;35(1):e12-e13AU/NZNational Heart Foundation of Australia and CSANZ, 2025
- Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2020;41:111-188. doi:10.1093/eurheartj/ehz455European Society of Cardiology and European Atherosclerosis Society, 2019
- Mach F, Koskinas KC, Roeters van Lennep JE et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190European Society of Cardiology and European Atherosclerosis Society, 2025
- Blumenthal RS, Morris PB, Gaudino M et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol 2026;87(19):2624-2757American College of Cardiology and American Heart Association (J Am Coll Cardiol), 2026
- Nissen SE, Lincoff AM, Brennan D et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). N Engl J Med 2023;388:1353-64New England Journal of Medicine, 2023
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback